Differences in interleukin-6, tumor necrosis factor, and procalcitonin levels in acute exacerbations of chronic obstructive pulmonary disease patients with and without secretome supplementatio
Phase 2
Completed
- Conditions
- Secretome eupplementation acts as an anti-inflammatory and immunomodulator which can be used as an additional therapy in AECOPD patients. Biomarkers interleukin-6 (IL-6), tumor necrosis factor (TNF) and procalcitonin (PCT) level in AECOPD patients.Acute exacerbation of chronic obstructive pulmonary disease patients
- Registration Number
- TCTR20230712001
- Lead Sponsor
- embaga Penelitian dan Pengabdian Kepada Masyarakat (LPPM) Sebelas Maret University Surakarta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
1. Patients diagnosed with acute exacerbation of COPD. Clinical symptoms of COPD exacerbation: worsening of symptoms (increasing shortness of breath, increased amount of sputum, and sputum purulence) compared to daily conditions.
2. Age over 40 years, based on the difference between the day of birth and the last birthday at the time of the study.
3. Willing to participate in the research and sign the informed consent.
Exclusion Criteria
1. AECOPD patients requiring ICU care and ventilators.
2. COPD patients with pleural effusion.
3. COPD patients with lung cancer.
4. COPD patients with HIV.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method interleukin-6 at 4th day of first intervention enzyme linked immunosorbent assay (ELISA),tumor necrosis factor-a at 4th day of first intervention enzyme linked immunosorbent assay (ELISA)
- Secondary Outcome Measures
Name Time Method procalcitonin at 4th day of first intervention enzyme linked immunosorbent assay (ELISA)